Trial reportJapanese journal of ophthalmology2026
Quality of life after cultured corneal endothelial cell transplant in patients with bullous keratopathy.
Trial report in Japanese journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeUsing the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25), to evaluate vision-related quality of life outcomes in patients with bullous keratopathy after cultured corneal endothelial cell (CEC) transplant. STUDY
designSingle-center prospective clinical trial
methodsIn this prospective, single-center study, 11 consecutive patients with bullous keratopathy underwent cultured CEC transplant. The NEI VFQ-25 was administered through in-person interviews by trained interviewers at baseline and at 24 weeks postoperatively. The NEI VFQ-25 comprises 12 subscales that assess different aspects of vision-related quality of life. Changes in composite and subscale scores were analyzed.
resultsThe patients comprised 5 men and 6 women, with a mean age of 64.4 years (range 49-82 years). All the patients had pseudophakic bullous keratopathy, with Fuchs endothelial corneal dystrophy being the predominant underlying cause of disease (7 eyes). The NEI VFQ-25 composite score improved significantly from 61.8 ± 11.9 to 79.5 ± 8.0 (P <.01). Significant improvements were observed in general vision, ocular pain, near vision, social function, mental health, role limitations, dependency, and peripheral vision subscales (P <.05). General health, distance vision, driving, and color vision subscales showed minimal improvement.
conclusionsCultured CEC transplant significantly improved vision-related quality of life in patients with bullous keratopathy. The comprehensive improvement across multiple NEI VFQ-25 domains suggests that this novel therapeutic approach may be a viable treatment option for corneal endothelial dysfunction.
Indexed as
Identifiers
40952553What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.